% IMPORTANT: The following is UTF-8 encoded.  This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.

@ARTICLE{Lalos:298918,
      author       = {F. Lalos and D. Flühs and M. Guberina and N. Bornfeld and
                      M. Stuschke$^*$ and W. Sauerwein and N. E. Bechrakis},
      title        = {{T}umor- and {R}adiation-{R}elated {C}omplications after
                      {R}uthenium-106 {B}rachytherapy in {S}mall to {M}edium
                      {U}veal {M}elanomas ({P}art 1). [{T}umor- und
                      strahlenbedingte {K}omplikationen nach
                      {R}uthenium-106-{B}rachytherapie bei kleinen bis
                      mittelgroßen {A}derhautmelanomen ({T}eil 1)].},
      journal      = {Klinische Monatsblätter für Augenheilkunde},
      volume       = {242},
      number       = {2},
      issn         = {0023-2165},
      address      = {Stuttgart},
      publisher    = {Thieme},
      reportid     = {DKFZ-2025-00354},
      pages        = {105 - 115},
      year         = {2025},
      abstract     = {The purpose of this study was to analyze tumor-related
                      complications after ruthenium-106 brachytherapy in patients
                      with uveal melanoma, with respect to local tumor control,
                      insufficient radiation response, enucleation, and metastasis
                      rate.This retrospective study included 608 patients treated
                      consecutively with ruthenium-106 brachytherapy between
                      January 2008 and December 2010 at the Department of
                      Ophthalmology, University Hospital Essen. The occurrence of
                      radiation-induced results was analyzed by estimating the
                      risk by applying the Kaplan-Meier method, i.e., the 'time to
                      event' analysis. The Cox model test was used for the
                      univariate and multivariate risk factor analyses. The median
                      follow-up was 51 months after primary treatment.Tumor
                      recurrence was found in 21 patients $(3.5\%)$ and repeated
                      treatment due to insufficient effect after the initial
                      ruthenium-106 brachytherapy was performed in 40 patients
                      $(6.6\%).$ The 5-year cumulative risk of recurrence was
                      $4.0\%$ and that of insufficient effect was $7.3\%.$
                      Thirteen patients $(2.1\%)$ underwent a secondary
                      enucleation; 8 because of a local recurrence and 5 because
                      of severe post-brachytherapy complications. The cumulative
                      enucleation risk was $2.3\%$ after 5 years and $2.9\%$ after
                      10 years, corresponding to eye preservation of 97.7 and
                      $97.1\%,$ respectively. In forty-two patients $(7.2\%),$
                      metastatic disease was diagnosed during the follow-up. The
                      metastatic rate as calculated by the Kaplan-Meier method was
                      9.0, and $13.1\%$ at 5 and 10 years, respectively.Our study
                      demonstrated that ruthenium-106 brachytherapy is an
                      excellent treatment option for achieving local tumor control
                      and eye preservation in well-selected patients. The
                      metastatic rate is in agreement with that of previous
                      studies analyzing small to medium size uveal melanomas.},
      keywords     = {Humans / Uveal Neoplasms: radiotherapy / Brachytherapy:
                      methods / Brachytherapy: adverse effects / Melanoma:
                      radiotherapy / Ruthenium Radioisotopes: therapeutic use /
                      Male / Female / Middle Aged / Aged / Retrospective Studies /
                      Adult / Radiation Injuries: etiology / Aged, 80 and over /
                      Treatment Outcome / Risk Factors / Neoplasm Recurrence,
                      Local: prevention $\&$ control / Neoplasm Recurrence, Local:
                      radiotherapy / Young Adult / Eye Enucleation / Prevalence /
                      Adolescent / Ruthenium Radioisotopes (NLM Chemicals) /
                      Ruthenium-106 (NLM Chemicals)},
      cin          = {ED01},
      cid          = {I:(DE-He78)ED01-20160331},
      pnm          = {899 - ohne Topic (POF4-899)},
      pid          = {G:(DE-HGF)POF4-899},
      typ          = {PUB:(DE-HGF)16},
      pubmed       = {pmid:38354842},
      doi          = {10.1055/a-2268-0985},
      url          = {https://inrepo02.dkfz.de/record/298918},
}